| Dr Johnsey L Leef Iii, MD | |
|
1120 Kanawha Blvd E, Charleston, WV 25301-2400 | |
| (304) 344-3457 | |
| (304) 344-3480 |
| Full Name | Dr Johnsey L Leef Iii |
|---|---|
| Gender | Male |
| Speciality | Diagnostic Radiology |
| Experience | 26 Years |
| Location | 1120 Kanawha Blvd E, Charleston, West Virginia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1568466050 | NPI | - | NPPES |
| 14175 | Medicaid | WV | |
| 2401716 | Medicaid | OH | |
| 2004387000 | Medicaid | WV | |
| 0130753 | Other | WV | UMWA |
| 14193 | Other | WV | CARELINK & CARELINK PEIA |
| 64065378 | Medicaid | KY | |
| H82323 | Other | WV | BRICKSTREET INSURANCE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0202X | Radiology - Diagnostic Radiology | 21155 (West Virginia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Charleston Area Medical Center | Charleston, WV | Hospital |
| Christus Spohn Hospital Corpus Christi | Corpus christi, TX | Hospital |
| Beckley Arh Hospital | Beckley, WV | Hospital |
| Greenbrier Valley Medical Center | Ronceverte, WV | Hospital |
| Harlan Arh Hospital | Harlan, KY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Rhn Clark Memorial Physician Practices Llc | 0840504114 | 85 |
| Associated Radiologists Inc | 1355249749 | 21 |
| Radiology Alliance Pc | 1850280470 | 204 |
| Premier Imaging And Intervention Pllc | 4587562335 | 21 |
| Virtual Radiologic Professionals Llc | 4981608817 | 355 |
| Singleton Associates Pa | 6305731118 | 691 |
| T J Samson Community Hospital | 0648182600 | 138 |
News Archive
Australian researchers have led a study published in the New England Journal of Medicine that shows a simple blood test can allow doctors to predict which HIV patients will have a side effect, known as a hypersensitivity reaction, to a particular medication before it is prescribed.
Microvisk Technologies, the developer of a handheld system to monitor the blood clotting status of patients taking the drug Warfarin, today announced that it has strengthened its Board with the appointment of medical industry veteran, Bill Moffitt, as Chairman and Peter Whitehouse as CFO.
Afraxis and PsychoGenics today announced an alliance to offer Afraxis' Enhanced Spine Platform (ESP) technology as part of PsychoGenics' comprehensive testing capabilities and drug discovery services.
ARMGO Pharma and the Muscular Dystrophy Association today announced that $1 Million has been awarded for preclinical work in support of an Investigational New Drug application with the U.S. Food and Drug Administration for ARM210, a novel, orally available, small-molecule Rycal drug that has potential as a treatment for Duchenne muscular dystrophy.
› Verified 3 days ago
| Entity Name | Appalachian Regional Healthcare Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477510162 PECOS PAC ID: 0840107835 Enrollment ID: O20031210000688 |
News Archive
Australian researchers have led a study published in the New England Journal of Medicine that shows a simple blood test can allow doctors to predict which HIV patients will have a side effect, known as a hypersensitivity reaction, to a particular medication before it is prescribed.
Microvisk Technologies, the developer of a handheld system to monitor the blood clotting status of patients taking the drug Warfarin, today announced that it has strengthened its Board with the appointment of medical industry veteran, Bill Moffitt, as Chairman and Peter Whitehouse as CFO.
Afraxis and PsychoGenics today announced an alliance to offer Afraxis' Enhanced Spine Platform (ESP) technology as part of PsychoGenics' comprehensive testing capabilities and drug discovery services.
ARMGO Pharma and the Muscular Dystrophy Association today announced that $1 Million has been awarded for preclinical work in support of an Investigational New Drug application with the U.S. Food and Drug Administration for ARM210, a novel, orally available, small-molecule Rycal drug that has potential as a treatment for Duchenne muscular dystrophy.
› Verified 3 days ago
| Entity Name | Associated Radiologists Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1649275728 PECOS PAC ID: 1355249749 Enrollment ID: O20031223000024 |
News Archive
Australian researchers have led a study published in the New England Journal of Medicine that shows a simple blood test can allow doctors to predict which HIV patients will have a side effect, known as a hypersensitivity reaction, to a particular medication before it is prescribed.
Microvisk Technologies, the developer of a handheld system to monitor the blood clotting status of patients taking the drug Warfarin, today announced that it has strengthened its Board with the appointment of medical industry veteran, Bill Moffitt, as Chairman and Peter Whitehouse as CFO.
Afraxis and PsychoGenics today announced an alliance to offer Afraxis' Enhanced Spine Platform (ESP) technology as part of PsychoGenics' comprehensive testing capabilities and drug discovery services.
ARMGO Pharma and the Muscular Dystrophy Association today announced that $1 Million has been awarded for preclinical work in support of an Investigational New Drug application with the U.S. Food and Drug Administration for ARM210, a novel, orally available, small-molecule Rycal drug that has potential as a treatment for Duchenne muscular dystrophy.
› Verified 3 days ago
| Entity Name | Premier Imaging And Intervention Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1285633370 PECOS PAC ID: 4587562335 Enrollment ID: O20050617000389 |
News Archive
Australian researchers have led a study published in the New England Journal of Medicine that shows a simple blood test can allow doctors to predict which HIV patients will have a side effect, known as a hypersensitivity reaction, to a particular medication before it is prescribed.
Microvisk Technologies, the developer of a handheld system to monitor the blood clotting status of patients taking the drug Warfarin, today announced that it has strengthened its Board with the appointment of medical industry veteran, Bill Moffitt, as Chairman and Peter Whitehouse as CFO.
Afraxis and PsychoGenics today announced an alliance to offer Afraxis' Enhanced Spine Platform (ESP) technology as part of PsychoGenics' comprehensive testing capabilities and drug discovery services.
ARMGO Pharma and the Muscular Dystrophy Association today announced that $1 Million has been awarded for preclinical work in support of an Investigational New Drug application with the U.S. Food and Drug Administration for ARM210, a novel, orally available, small-molecule Rycal drug that has potential as a treatment for Duchenne muscular dystrophy.
› Verified 3 days ago
| Entity Name | Virtual Radiologic Professionals Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1932342029 PECOS PAC ID: 4981608817 Enrollment ID: O20170612002104 |
News Archive
Australian researchers have led a study published in the New England Journal of Medicine that shows a simple blood test can allow doctors to predict which HIV patients will have a side effect, known as a hypersensitivity reaction, to a particular medication before it is prescribed.
Microvisk Technologies, the developer of a handheld system to monitor the blood clotting status of patients taking the drug Warfarin, today announced that it has strengthened its Board with the appointment of medical industry veteran, Bill Moffitt, as Chairman and Peter Whitehouse as CFO.
Afraxis and PsychoGenics today announced an alliance to offer Afraxis' Enhanced Spine Platform (ESP) technology as part of PsychoGenics' comprehensive testing capabilities and drug discovery services.
ARMGO Pharma and the Muscular Dystrophy Association today announced that $1 Million has been awarded for preclinical work in support of an Investigational New Drug application with the U.S. Food and Drug Administration for ARM210, a novel, orally available, small-molecule Rycal drug that has potential as a treatment for Duchenne muscular dystrophy.
› Verified 3 days ago
| Entity Name | Radiology Alliance Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1861478489 PECOS PAC ID: 1850280470 Enrollment ID: O20200406000385 |
News Archive
Australian researchers have led a study published in the New England Journal of Medicine that shows a simple blood test can allow doctors to predict which HIV patients will have a side effect, known as a hypersensitivity reaction, to a particular medication before it is prescribed.
Microvisk Technologies, the developer of a handheld system to monitor the blood clotting status of patients taking the drug Warfarin, today announced that it has strengthened its Board with the appointment of medical industry veteran, Bill Moffitt, as Chairman and Peter Whitehouse as CFO.
Afraxis and PsychoGenics today announced an alliance to offer Afraxis' Enhanced Spine Platform (ESP) technology as part of PsychoGenics' comprehensive testing capabilities and drug discovery services.
ARMGO Pharma and the Muscular Dystrophy Association today announced that $1 Million has been awarded for preclinical work in support of an Investigational New Drug application with the U.S. Food and Drug Administration for ARM210, a novel, orally available, small-molecule Rycal drug that has potential as a treatment for Duchenne muscular dystrophy.
› Verified 3 days ago
| Entity Name | Singleton Associates Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1538107875 PECOS PAC ID: 6305731118 Enrollment ID: O20230214000913 |
News Archive
Australian researchers have led a study published in the New England Journal of Medicine that shows a simple blood test can allow doctors to predict which HIV patients will have a side effect, known as a hypersensitivity reaction, to a particular medication before it is prescribed.
Microvisk Technologies, the developer of a handheld system to monitor the blood clotting status of patients taking the drug Warfarin, today announced that it has strengthened its Board with the appointment of medical industry veteran, Bill Moffitt, as Chairman and Peter Whitehouse as CFO.
Afraxis and PsychoGenics today announced an alliance to offer Afraxis' Enhanced Spine Platform (ESP) technology as part of PsychoGenics' comprehensive testing capabilities and drug discovery services.
ARMGO Pharma and the Muscular Dystrophy Association today announced that $1 Million has been awarded for preclinical work in support of an Investigational New Drug application with the U.S. Food and Drug Administration for ARM210, a novel, orally available, small-molecule Rycal drug that has potential as a treatment for Duchenne muscular dystrophy.
› Verified 3 days ago
| Entity Name | Imaging Associates Of Indiana Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1699072611 PECOS PAC ID: 1254503345 Enrollment ID: O20230330002744 |
News Archive
Australian researchers have led a study published in the New England Journal of Medicine that shows a simple blood test can allow doctors to predict which HIV patients will have a side effect, known as a hypersensitivity reaction, to a particular medication before it is prescribed.
Microvisk Technologies, the developer of a handheld system to monitor the blood clotting status of patients taking the drug Warfarin, today announced that it has strengthened its Board with the appointment of medical industry veteran, Bill Moffitt, as Chairman and Peter Whitehouse as CFO.
Afraxis and PsychoGenics today announced an alliance to offer Afraxis' Enhanced Spine Platform (ESP) technology as part of PsychoGenics' comprehensive testing capabilities and drug discovery services.
ARMGO Pharma and the Muscular Dystrophy Association today announced that $1 Million has been awarded for preclinical work in support of an Investigational New Drug application with the U.S. Food and Drug Administration for ARM210, a novel, orally available, small-molecule Rycal drug that has potential as a treatment for Duchenne muscular dystrophy.
› Verified 3 days ago
| Entity Name | Arh Mary Breckinridge Health Services, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1952894826 PECOS PAC ID: 8123293818 Enrollment ID: O20230531001093 |
News Archive
Australian researchers have led a study published in the New England Journal of Medicine that shows a simple blood test can allow doctors to predict which HIV patients will have a side effect, known as a hypersensitivity reaction, to a particular medication before it is prescribed.
Microvisk Technologies, the developer of a handheld system to monitor the blood clotting status of patients taking the drug Warfarin, today announced that it has strengthened its Board with the appointment of medical industry veteran, Bill Moffitt, as Chairman and Peter Whitehouse as CFO.
Afraxis and PsychoGenics today announced an alliance to offer Afraxis' Enhanced Spine Platform (ESP) technology as part of PsychoGenics' comprehensive testing capabilities and drug discovery services.
ARMGO Pharma and the Muscular Dystrophy Association today announced that $1 Million has been awarded for preclinical work in support of an Investigational New Drug application with the U.S. Food and Drug Administration for ARM210, a novel, orally available, small-molecule Rycal drug that has potential as a treatment for Duchenne muscular dystrophy.
› Verified 3 days ago
| Entity Name | Rhn Clark Memorial Physician Practices Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1083098651 PECOS PAC ID: 0840504114 Enrollment ID: O20230816002093 |
News Archive
Australian researchers have led a study published in the New England Journal of Medicine that shows a simple blood test can allow doctors to predict which HIV patients will have a side effect, known as a hypersensitivity reaction, to a particular medication before it is prescribed.
Microvisk Technologies, the developer of a handheld system to monitor the blood clotting status of patients taking the drug Warfarin, today announced that it has strengthened its Board with the appointment of medical industry veteran, Bill Moffitt, as Chairman and Peter Whitehouse as CFO.
Afraxis and PsychoGenics today announced an alliance to offer Afraxis' Enhanced Spine Platform (ESP) technology as part of PsychoGenics' comprehensive testing capabilities and drug discovery services.
ARMGO Pharma and the Muscular Dystrophy Association today announced that $1 Million has been awarded for preclinical work in support of an Investigational New Drug application with the U.S. Food and Drug Administration for ARM210, a novel, orally available, small-molecule Rycal drug that has potential as a treatment for Duchenne muscular dystrophy.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Johnsey L Leef Iii, MD Po Box 11137, Charleston, WV 25339-1137 Ph: (304) 344-3457 | Dr Johnsey L Leef Iii, MD 1120 Kanawha Blvd E, Charleston, WV 25301-2400 Ph: (304) 344-3457 |
News Archive
Australian researchers have led a study published in the New England Journal of Medicine that shows a simple blood test can allow doctors to predict which HIV patients will have a side effect, known as a hypersensitivity reaction, to a particular medication before it is prescribed.
Microvisk Technologies, the developer of a handheld system to monitor the blood clotting status of patients taking the drug Warfarin, today announced that it has strengthened its Board with the appointment of medical industry veteran, Bill Moffitt, as Chairman and Peter Whitehouse as CFO.
Afraxis and PsychoGenics today announced an alliance to offer Afraxis' Enhanced Spine Platform (ESP) technology as part of PsychoGenics' comprehensive testing capabilities and drug discovery services.
ARMGO Pharma and the Muscular Dystrophy Association today announced that $1 Million has been awarded for preclinical work in support of an Investigational New Drug application with the U.S. Food and Drug Administration for ARM210, a novel, orally available, small-molecule Rycal drug that has potential as a treatment for Duchenne muscular dystrophy.
› Verified 3 days ago
Matthew W. Morris, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 1120 Kanawha Blvd E, Charleston, WV 25301 Phone: 304-344-3457 Fax: 304-344-3480 | |
Dr. Mary H.l. Mcjunkin, M.D. Radiology Medicare: Not Enrolled in Medicare Practice Location: 1120 Kanawha Blvd E, Charleston, WV 25301 Phone: 304-344-3457 Fax: 304-344-3480 | |
Ravindra K Gogineni, M.D. Radiology Medicare: Not Enrolled in Medicare Practice Location: 1021 Quarrier St, Ste 301, Charleston, WV 25301 Phone: 304-343-4625 Fax: 304-343-4626 | |
Dr. John F. Mega, M.D. Radiology Medicare: Medicare Enrolled Practice Location: 1120 Kanawha Blvd E, Charleston, WV 25301 Phone: 304-344-3457 Fax: 304-344-3480 | |
Riad Al-asbahi, M.D. Radiology Medicare: Not Enrolled in Medicare Practice Location: 1021 Quarrier St, Ste 301, Charleston, WV 25301 Phone: 304-343-4625 Fax: 304-343-4626 | |
Dr. Jennifer M. Smith, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 1120 Kanawha Blvd E, Charleston, WV 25301 Phone: 304-344-3457 Fax: 304-344-3480 | |
Timothy Aaron Vanhoose, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 1120 Kanawha Blvd E, Charleston, WV 25301 Phone: 304-344-3457 Fax: 304-344-3480 |